Cargando…
VALTOCO(®) (Diazepam Nasal Spray) for the Acute Treatment of Intermittent Stereotypic Episodes of Frequent Seizure Activity
Valtoco(®) is a new FDA-approved nasal spray version of diazepam indicated for the treatment of acute, intermittent, and stereotypic episodes of frequent seizure activity in epilepsy patients six years of age and older. Although IV and rectal diazepam are already used to treat seizure clusters, Valt...
Autores principales: | Cornett, Elyse M., Amarasinghe, Sam N., Angelette, Alexis, Abubakar, Tunde, Kaye, Adam M., Kaye, Alan David, Neuchat, Elisa E., Urits, Ivan, Viswanath, Omar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931041/ https://www.ncbi.nlm.nih.gov/pubmed/33670456 http://dx.doi.org/10.3390/neurolint13010007 |
Ejemplares similares
-
Pharmacokinetics and safety of VALTOCO (NRL‐1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri‐ictal) and nonseizure (interictal) conditions: A phase 1, open‐label study
por: Hogan, Robert Edward, et al.
Publicado: (2020) -
Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
por: Berger, Amnon A., et al.
Publicado: (2020) -
Consistent safety and tolerability of Valtoco(®) (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long‐term, open‐label, repeat‐dose safety study
por: Miller, Ian, et al.
Publicado: (2021) -
Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out‐of‐hospital seizure clusters: Results from a phase 3, open‐label, repeat‐dose safety study
por: Sperling, Michael R., et al.
Publicado: (2022) -
Anesthesia Medications and Interaction with Chemotherapeutic Agents
por: Watson, Jeremy, et al.
Publicado: (2021)